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months (95% CI 4.0–12.5), p  ! 0.0001. The concordance prob-
abilities for CLIP and I-CLIP were 0.7037 and 0.7096, respec-
tively (p  ! 0.0001).  Conclusions: Our preliminary results indi-
cate that I-CLIP significantly improved prognostic stratifica-
tion of patients with advanced HCC. However, independent 
validation of our study is warranted. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) develops as a conse-
quence of underlying chronic liver disease (CLD), most 
commonly cirrhosis due to viral hepatitis. Therefore, the 
majority of patients with HCC suffer from two co-existing 
competing causes of morbidity and mortality, the severity 
of their CLD and the HCC tumor stage. This syndrome of 
the two-disease state directly affects survival, which in 
turn affects patients’ prognostic stratification and treat-
ment decisions in clinical trials and in clinical practice. 
Therefore, most of the HCC staging systems include a 
combination of variables related to the tumor stage and 
the status of the CLD. However, several challenges face the 
clinical utility of these staging systems. First, their perfor-
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 Abstract 
 Objective: Improving the prognostic stratification of unre-
sectable hepatocellular carcinoma (HCC) patients is critically 
needed. Since patients’ survival is closely linked to the sever-
ity of the underlying liver disease, and insulin-like growth 
factor-1 (IGF-1) is produced predominantly in the liver, we 
hypothesized that IGF-1 may correlate with patients’ survival 
and hence improve the prognostic ability of the Cancer of 
the Liver Italian Program (CLIP) score.  Methods: Baseline 
plasma IGF-1 and clinicopathologic parameters were avail-
able from 288 patients. Multivariate Cox regression models, 
Kaplan-Meier curves, and the log-rank test were applied. Re-
cursive partitioning was used to determine the optimal cut 
point for IGF-1 using training/validation samples. Prognostic 
ability of the I-CLIP (I = IGF) was compared to CLIP using C-
index.  Results: IGF-1 significantly correlated with the clini-
copathologic features. With an optimal IGF-1 cut point of
26 ng/ml, the overall survival of patients with IGF-1  1 26 was 
17.7 months (95% CI 13.6–22.8), and with IGF-1  ^  26 was 5.8 
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mance is highly variable because they were developed 
from different patient populations, surgical and nonsur-
gical, and they depend on many factors including patient 
demographics. Secondly, they lack the integration of new 
biologic biomarkers that correlate with the tumor param-
eters and with the severity of the underlying CLD. In this 
context, non-invasive means of obtaining those markers 
is essential, given the challenges in obtaining tissue sam-
ples in patients with cirrhosis and coagulation disorders 
that put HCC patients at risk for complications following 
needle biopsies.
 The Cancer of the Liver Italian Program (CLIP) score 
 [1] and the Barcelona Clinic Liver Cancer (BCLC) staging 
system  [2] are among the most commonly used HCC 
prognostic systems to stratify patients on clinical trials in 
the Western world. The BCLC staging system  [2] is en-
dorsed by the American Association for the Study of Liv-
er Diseases (AASLD) and the European Association for 
the Study of Liver Diseases (EASL) clinical practice guide-
lines  [3, 4] . Notably, our most recent publication com-
pared the prognostic accuracy of the CLIP score to that 
of the BCLC staging in our patient population using the 
C-index, and found that the concordance probabilities 
for BCLC and CLIP were 0.65 and 0.70, respectively  [5] . 
Using U-statistics, the difference was significant and the 
p value was 0.007. Thus, these results indicate that the 
CLIP scoring system better predicted survival than BCLC 
staging in our patient population.
 The CLIP score is a prognostic system that assigns 
points for the Child-Pugh score, tumor morphology (sol-
itary,  ^  50% of the liver, massive), serum   -fetoprotein 
(AFP), and presence or absence of portal vein thrombus 
 [1] . Notably, many studies validated the use of CLIP in 
HCC patients  [6–15] . Furthermore, recent studies, in-
cluding one of our patient population  [5] , evaluated the 
predictive accuracy of different HCC staging systems and 
showed that the CLIP score was more predictive than 
BCLC in the studied patient populations, which included 
a significant number of patients with advanced HCC  [5, 
16, 17] . However, the two systems are conceptually differ-
ent and cannot be directly compared. The BCLC staging 
system was originally designed as a treatment allocation 
algorithm and subsequently evolved as one of the stan-
dard systems to stage HCC patients, whereas the CLIP 
score is a prognostic system that was designed to stratify 
patients according to their expected survival. In addition, 
several studies indicated that about 80% of the CLIP pa-
tient population is classified as a CLIP score of 0–3  [5, 9, 
10] ; therefore, there is an unmet need to improve the ac-
curacy of CLIP score stratification.
 Insulin-like growth factor-1 (IGF-1) is a hormone that 
is predominantly synthesized in the liver  [18] . Therefore, 
low circulating IGF-1 levels have been found to be associ-
ated with CLD, such as steatosis, chronic hepatitis C, cir-
rhosis, non-alcoholic steatohepatitis, and HCC  [19–25] . 
Collectively, these data suggest that circulating levels of 
IGF-1 may reflect the synthetic function of the liver and 
correlate with patients’ advanced CLD status, which di-
rectly affects the survival of patients with HCC indepen-
dent of their tumor stage.
 However, evaluating the role of IGF-1 in predicting 
survival of patients with HCC and in refining their prog-
nostic stratification has not been studied yet. Therefore, 
we hypothesized that baseline plasma levels of IGF-1 will 
correlate with the clinicopathologic features and survival 
of patients with HCC and hence may improve the predic-
tive ability of the CLIP score for HCC.
 Patients and Methods 
 Study Population 
 After obtaining MD Anderson’s Institutional Review Board 
approval and patients’ informed consent, we enrolled new pa-
tients with pathologically proven HCC. We excluded patients 
with concurrent presence or history of other malignancies, in-
cluding other types of primary liver cancer (such as bile duct can-
cers or fibrolamellar HCC). Patients’ medical records were re-
viewed for baseline clinical, laboratory, pathologic, staging, and 
radiologic features. We recruited 394 eligible patients; baseline 
plasma samples were available for 288 only who returned for 
blood samples collection. There were no significant differences 
between our study population and patients who were missed, ei-
ther in their age, race, and gender, hepatitis status, diabetes his-
tory, alcohol consumption, smoking, Child-Pugh score, cirrhosis; 
pathological cellular differentiation; serum albumin, or CLIP 
scoring. However, patients without blood samples had a tendency 
to have multinodular tumor, higher AFP levels, portal vein 
thrombosis, and higher incidence of tumor size involving  ! 50% 
of the liver. Overall survival time was calculated to reflect the 
time between diagnosis and last follow-up visit or death.
 Baseline Plasma IGF-1 
 Baseline venous blood samples (3–5 ml of the whole blood) 
were collected, anticoagulated by ethylenediaminetetraacetic 
acid (EDTA) and centrifuged at 4  °  C and 3,000 r.p.m. for 15 min. 
The plasma samples were then removed, aliquoted, and snap fro-
zen at –20  °  C. IGF-1 was tested using ELISA (Quantikine Human 
IGF-1 Immunoassay ELISA Kit; R&D Systems, Minneapolis, 
Minn., USA). The plasma biomarker level was determined from a 
standard curve generated for each of the sample sets assayed after 
duplicate measurements were made.
 Statistical Analysis 
 We used Cox regression to assess factors associated with over-
all survival, and Wilcoxon rank sum test to study the correlation 
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between baseline IGF-1 and various clinical characteristics and 
staging systems. To identify an optimal IGF-1 cut point, recursive 
partitioning methodology  [26] was used to split the data random-
ly into training (2/3) and validation (test) (1/3) sets. We used the 
training set to find the optimal cut point maximizing the sur-
vival difference between the low and high IGF-1 groups, and then 
validated the cut point by fitting a Cox regression model to the 
dichotomized IGF-1 value on the test data. We repeated this 
methodology using 20 different random splits. Next, we fitted the 
multivariable Cox regression models including IGF-1, dichoto-
mized at the optimal cut point, and the variables within the CLIP 
system, to evaluate whether IGF-1 was an independent prognostic 
factor after adjusting for the CLIP variables. Finally, the median 
survival was computed in each I-CLIP (I = IGF) group (0, 1, 2, 3, 
4, and 5+) and the groups were compared using log-rank tests, to 
assess the performance of the I-CLIP in comparison to the CLIP. 
The sign test was used to assess whether the IGF-1-low groups 
tended to have shorter median survival within the CLIP and I-
CLIP groups than IGF-1-high groups. The prognostic ability of 
the CLIP and I-CLIP was compared using a C-index test, with 
secondary analyses done to compute a partial C-index analysis, 
which computed the C-index using only patients whose class sta-
tus changed between CLIP and I-CLIP.
 Results 
 Patient Characteristics 
 For the entire cohort of 288 patients, the median over-
all survival was 13.8 months, (95% CI 11.7–17.3). Baseline 
patients’ characteristics are shown in  table 1 . The Cox re-
gression models indicated that vascular invasion, tumor 
differentiation and nodularity, high serum level of AFP, 
bilirubin, alanine transaminase (ALT), aspartate trans-
aminase (AST), presence of cirrhosis, a Child-Pugh score 
of B or C, and extrahepatic metastasis were all significant 
predictors of shorter overall survival.
 Prognostic Factors of Survival in Our Patient 
Population 
 Most recently, we reported that the discriminative 
ability of the CLIP score was better than that of the BCLC 
staging system in our patient population  [5] . In that study, 
we applied a multivariable Cox regression model to our 
data including the factors contained in the CLIP score to 
validate the CLIP scoring system in our patient popula-
tion. Only 285 patients were included because AFP val-
ues were missing for 3 patients. The study hazard ratios 
(HRs) were very close to the HRs reported in the original 
CLIP paper  [1] . The CLIP score stratified our patients 
very effectively into different prognostic categories (p  ! 
0.0001).
Table 1.  Patient Characteristics
Variable Patients, n (%) 
(n = 288)
Age
<60 years 111 (38.5)
≥60 years 177 (61.5)
Gender
Female 89 (30.9)
Male 199 (69.1) 
Serum AFP level
<400 ng/ml 199 (69.1)
≥400 ng/ml 86 (29.8)
Missing 3 (1.0)
Tumor differentiation
Well 112 (38.9)
Moderate 95 (33.0)
Poor 50 (17.4)
Unknown 31 (10.8)
Tumor size
≤50% of liver 191 (66.3)
>50% of liver 97 (33.7)
Vascular invasion
Yes 53 (18.4)
No 235 (81.6)
Distant metastasis
Yes 60 (20.8)
No 228 (79.2)
Hepatitis infection status
HBV 38 (13.2)
HCV 60 (20.8)
HCV + HBV 27 (9.4)
None 163 (56.6) 
Nodularity
Uninodular 105 (36.5)
Multinodular 183 (63.5)
Lymph node involvement
Yes 122 (42.4)
No 166 (57.6)
Bilirubin level
≤1.6 mg/dl 260 (90.3)
>1.6 mg/dl 28 (9.7)
Cirrhosis
Yes 173 (60.1)
No 115 (39.9)
Child-Pugh class
A 206 (71.5)
B 76 (26.4)
C 6 (2.1)
H BV = Hepatitis B virus; HCV = hepatitis C virus.
Reprinted with permission from Kaseb et al. [5]. © 2011 Amer-
ican Cancer Society, Inc.
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Table 2. C orrelations between plasma IGF-1 level and patient 
characteristics by the Wilcoxon rank-sum test
Patient characteristic Patients
n (%)
(n = 288)
Plasma IGF-1 
level (ng/ml)
mean 8 SE
p
Age
<60 years 111 (38.5) 59.37845.35 0.07
≥60 years 177 (61.5) 50.95835.57
Race
Non-White 89 (30.9) 53.51842.82 0.84
White 199 (69.1) 49.55835.42
Gender
Female 89 (30.9) 59.16842.87 0.14
Male 199 (69.1) 51.97835.17
Hepatitis infection status
HBV 38 (13.2) 56.07849.16 0.047
HCV 60 (20.8) 52.33832.27
HBV + HCV 27 (9.4) 35.77822.24
None 163 (56.6) 57.50838.07
Serum AFP level
<400 ng/ml 199 (69.1) 56.46836.03 0.08
≥400 ng/ml 86 (29.9) 49.62841.84
Unknown 3 (1.0)
Tumor differentiation
Well 112 (38.9) 55.23836.47 0.63
Moderate 95 (33.0) 56.63838.19
Poor 50 (17.4) 48.29838.48
Unknown 31 (10.8) 52.51840.83
Tumor nodularity
Uninodular 105 (36.5) 63.25842.01 0.002
Multinodular 183 (63.5) 49.00834.19
Tumor size
≤50% of the liver 191 (66.3) 60.11841.33 0.0002
>50% of the liver 97 (33.7) 42.54826.10
Vascular invasion
No 235 (81.6) 56.73839.40 0.016
Yes 53 (18.4) 42.94827.19
Lymph node involvement
No 166 (57.6) 53.79833.58 0.83
Yes 122 (42.4) 54.75849.19
Distant metastasis
No 228 (79.2) 54.40838.09 0.85
Yes 60 (20.8) 53.39836.93
Bilirubin level
≤1.6 mg/dl 260 (90.3) 56.84838.03 0.0003
>1.6 mg/dl 28 (9.7) 29.63824.73
Child-Pugh class
A 206 (71.5) 59.05838.62 0.0021
B 76 (26.4) 42.49832.60
C 6 (2.1) 35.77837.38
ALT level
≤40 U/l 134 (46.5) 59.71843.40 0.02
>40 U/l 153 (53.1) 49.39831.59
Unknown 1 (0.4)
AST level
≤45 U/l 88 (30.6) 68.54842.18 <0.0001
>45 U/l 179 (62.2) 47.26833.68
Unknown 21 (7.3) 53.20836.31
H BV = Hepatitis B virus; HCV = hepatitis C virus; SE = standard error.
Table 3.  Univariate Cox proportional hazards regression analy-
sis
Predictor HR 95% CI 
of HR
p
Gender (male vs. female) 1.44 1.06–1.96 0.018
Age (>60 vs. ≤60 years) 0.88 0.66–1.16 0.351
Race (White vs. non-White) 0.75 0.56–1.00 0.051
Hepatitis virus infection 
No infection vs. HBV + HCV 0.51 0.32–0.80 0.004
HBV alone vs. HBV + HCV 0.76 0.44–1.32 0.334
HCV alone vs. HBV + HCV 0.72 0.43–1.18 0.192
Tumor differential (poor vs. other) 1.63 1.15–2.31 0.006
AFP (≥400 vs. <400 ng/ml) 2.26 1.69–3.02 <0.0001
Tumor nodularity (multi vs. uni) 2.28 1.68–3.11 <0.0001
Tumor size (>50 vs. ≤50%) 2.92 2.19–3.90 <0.0001
Vascular invasive (yes vs. no) 2.65 1.90–3.70 <0.0001
Metastasis (yes vs. no) 1.76 1.27–2.45 0.001
Lymph node involvement 
(yes vs. no) 1.82 1.38–2.40 <0.0001
Bilirubin (>1.6 vs. ≤1.6 ng/ml) 2.74 1.78–4.22 <0.0001
Serum AST (>45 vs. ≤45 U/l) 2.17 1.57–3.00 <0.0001
Serum ALT (>40 vs. ≤40 U/l) 1.77 1.34–2.34 <0.0001
Cirrhosis (yes vs. no) 1.35 1.02–1.79 0.036
Treatment 
Chemotherapy vs. none 0.56 0.38–0.84 0.0047
Surgery vs. none 0.19 0.12–0.31 <0.0001
Chemoembolization vs. none 0.38 0.22–0.67 0.0008
IGF-1 (<26 vs. ≥26 ng/ml) 2.06 1.5–2.81 <0.0001
Reprinted with permission from Kaseb et al. [5]. © 2011 Amer-
ican Cancer Society, Inc.
Table 4.  Multivariable Cox proportional hazards model for I-
CLIP: CLIP score variables + IGF-1 dichotomized by 26 ng/ml
I-CLIP score variables HR 95% CI 
of HR
p 
Child-Pugh
B vs. A 1.69 1.22–2.33 0.001
C vs. A 2.84 1.12–7.22 0.03
Tumor morphology
1 vs. 0 1.67 1.15–2.43 0.007
2 vs. 0 3.65 2.46–5.42 <0.0001
AFP
≥400 vs. <400 ng/ml 1.72 1.26–2.34
0.0006
Portal thrombosis
yes vs. no 1.41 0.89–2.23 0.14
IGF-1
≤26 vs. >26 ng/ml 1.53 1.09–2.13 0.01
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 Baseline Plasma Levels of IGF-1 as an Independent 
Prognostic Factor 
 Table  2 describes the correlations between plasma 
IGF-1 level and patient characteristics by the Wilcox-
on rank-sum test. Univariate Cox regression analyses 
showed that baseline plasma IGF-1 level was most sig-
nificantly associated with Child-Pugh score, bilirubin, 
AST levels, tumor size and nodularity, and vascular inva-
sion; however, the strongest association was with AST 
level (p  ! 0.0001;  table 3 ).
 Identifying the Optimal Cut Points of Plasma IGF-1 in 
Our Patient Population 
 We applied the recursive partitioning test to random-
ly selected training/test sets to find the optimal single cut 
point for baseline IGF-1 in terms of predicting survival. 
We found that 8 of the 20 sets found roughly the same 
optimal cut points of 26 ng/ml. Our results suggest that 
patients with low IGF-1 ( ! 26 ng/ml) had shorter median 
overall survival. When ‘low IGF-1’ was considered in a 
univariate Cox regression model fit to the entire data set, 
this effect was highly significant (p  ! 0.0001; HR 2.06; 
95% CI 1.50–2.81). The median overall survival time es-
timate for patients with IGF-1  1 26 was 17.7 months (95% 
CI 13.6–22.8), and for IGF-1  ^  26 was 5.8 months (95% 
CI 4.0–12.5; p  ! 0.0001; see Kaplan-Meier estimates; 
 fig. 1 ).
 Constructing the I-CLIP Scoring System 
 Our current multivariate analysis, using the dichoto-
mized value of IGF-1, indicated that IGF-1 was a signifi-
cant independent prognostic factor for overall survival, 
even after adjusting for CLIP parameters (p = 0.01; HR 
1.53; 95% CI 1.09–2.13;  table 4 ). We also observed that 
IGF-1 incorporation in the CLIP score did not alter the 
HRs for the CLIP parameters.
 Baseline Plasma IGF-1 Separates High- and Low-Risk 
Groups within Each CLIP Score 
 Patients within each CLIP score group were split ac-
cording to whether they had low/high IGF-1. Within each 
CLIP or I-CLIP score, the estimated median overall sur-
vival for IGF-1-high patients was higher than the medi-
an overall survival for IGF-1-low patients. We observed 
strong trends that were not statistically significant in the 
scoring system groups ( table  5 ). However, this was not 
surprising, given the extremely low power for detecting 
such differences given the small number of IGF-1-low 
subjects ( ^  15) within all groups. However, our overall 
sign test that compared low and high IGF-1 groups and 
assessed the prognostic information of IGF-1 was signif-
icant (p = 0.031). Therefore, our preliminary results indi-
cated that the estimated median overall survival was 
greater in IGF-1-high patients within all groups, which 
contain independent patients, indicating that those pa-
tients within all scores tended to have better prognosis 
than IGF-1-low patients.
 Our preliminary scoring system, named I-CLIP, inte-
grates a dichotomized IGF-1 level into the CLIP score 
variables; score between 0 and 7 for each patient ( table 6 ). 
Specifically, the I-CLIP scoring system was computed in 
the following way: CLIP score + IGF-1 score (1 if IGF 
 ^  26, and 0 if IGF  1 26). Based on the C-index analysis 
that compared the prognostic ability of the two systems, 
the concordance probabilities for CLIP and I-CLIP were 
0.7037 and 0.7096, respectively. U-statistics indicated that 
the differences in C-index were statistically significant
(p  ! 0.0001). Computing a ‘partial’ C-index using only 
subjects whose group membership changed between 
CLIP and I-CLIP (0.547 for CLIP, 0.617 for I-CLIP), we 
observed that the IGF-1-low subjects were better classi-
fied when moved into the next higher risk group by I-
CLIP. The calculated C-index for the V-CLIP (V = VEGF) 
score was 0.7041, and the U-statistics p value for I-CLIP 
versus V-CLIP was 0.056.  Figure 2 contains the Kaplan-
Meier plots for the separate CLIP groups, and  figure 3 
contains the Kaplan-Meier plots for the separate I-CLIP 
groups. CLIP 4 and 5 were joined as one group (4+), and 
I-CLIP 4, 5 and 6 were joined as one group (4+).
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 Fig. 1. Kaplan-Meier estimates of overall survival (OS). 
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Table 5.  Log-rank test on overall survival (OS) for CLIP groups split by IGF-1 (IGF-1 = 0 if IGF >26; IGF-1 = 1 
if IGF ≤26)
CLIP Varname Level Patients
n
Eventa Median OS time 
months (95% CI) 
p Power
0 All patients 54 26 36.49 (28.73, 67.2)
IGF-1 0 45 21 36.49 (29, NA) 0.5697 0.13
1 9 5 21.4 (6.84, NA)
1 All patients 80 54 22.65 (17.85, 34.19)
IGF-1 0 74 49 22.78 (18.97, 36.33) 0.2851 0.07
1 6 5 16.88 (16.31, NA)
2 All patients 77 65 12.2 (9.83, 15.52)
IGF-1 0 62 51 12.69 (9.93, 20.58) 0.1386 0.24
1 15 14 8.35 (5.06, 17.1)
3 All patients 52 48 6.02 (4.18, 10.42)
IGF-1 0 38 35 7.68 (5.85, 12.69) 0.124 0.67
1 14 13 3.63 (2.27, NA)
4 All patients 19 19 2.37 (2.14, 12.46)
IGF-1 0 7 7 2.14 (0.95, NA) 0.9114 0.14
1 12 12 3.17 (2.3, NA)
5 All patients 6 5 2.66 (2.37, NA)
IGF-1 0 2 1 2.37 (NA, NA) 0.3508 0.09
1 4 4 2.68 (0.62, NA)
a  Event = death.
Table 6.  I-CLIP scoring system (0–7)
I-CLIP score variable S cores
0 1 2
Child-Pugh stage A B C
Tumor morphology uninodular and ≤50% multinodular and ≤50% massive or >50%
AFP <400 ng/ml ≥400 ng/ml
Portal vein thrombosis no yes
IGF-1 >26 ng/ml ≤26 ng/ml
Table 7. M ultivariable Cox proportional hazards model for IV-CLIP: CLIP score variables + IGF-1 dichotomized 
by 26 ng/ml + VEGF dichotomized by 450 pg/ml
IV-CLIP score variables HR 95% CI of HR p 
Child-Pugh B vs. A 1.69 1.22–2.33 0.001
C vs. A 2.84 1.12–7.22 0.03
Tumor morphology 1 vs. 0 1.67 1.15–2.43 0.007
2 vs. 0 3.65 2.46–5.42 <0.0001
AFP ≥400 vs. <400 ng/ml 1.72 1.26–2.34 0.0006
Portal thrombosis yes vs. no 1.41 0.89–2.23 0.14
IGF-1 ≤26 vs. >26 ng/ml 1.53 1.09–2.13 0.01
VEGF >450 vs. ≤450 pg/ml 1.57 1.12–2.22 0.01
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 Constructing an IV-CLIP Scoring System 
 Our current multivariate analysis, using the dichoto-
mized values of both biomarkers, indicated that IGF-1 
and the VEGF were significant independent prognostic 
factors for overall survival, even after adjusting for CLIP 
parameters (for IGF-1: p = 0.01, HR 1.53, 95% CI 1.09–
2.13, and for VEGF: p = 0.01, HR 1.57, 95% CI 1.12–2.22; 
 table 7 ). We also observed that IGF-1 and VEGF incorpo-
ration into the CLIP score did not alter the HRs for the 
CLIP factors. However, the C-index analysis for IV-CLIP 
was 0.7092, almost identical to that of the I-CLIP (0.7096).
 Discussion 
 One of the major challenges in HCC management is 
prediction of survival and prognosis, given the marked 
heterogeneity noted in patients with HCC because of the 
two-disease state of CLD and HCC that independently 
affects their survival and prognosis. Our most recent 
study  [12] introduced the V-CLIP score, integrating base-
line plasma VEGF, as a marker that was shown in several 
studies to correlate with the tumor staging and invasive-
ness  [27] , into the CLIP score, and it showed significant 
improvement in prediction of survival. However, since 
accurate assessment of the status of the CLD is also es-
sential to determine both short- and long-term prognosis 
and to make therapy decisions in patients with HCC, 
there is an unmet need for non-invasive liver reserve bio-
markers to assess the severity of the CLD. Our current 
study aimed at evaluating the utility of plasma IGF-1
in this setting since it is synthesized mainly by the liver 
and significantly decreases in CLD and cirrhosis  [19–22] . 
Therefore, our current score, I-CLIP, takes into account 
assessing a baseline plasma biomarker that is shown in 
our patient population to correlate with the CLD condi-
tion, using non-invasive molecular assays. Our combined 
clinical and laboratory index using plasma IGF-1 and pa-
rameters of the CLIP score is advantageous since it is eas-
ily calculated and could be replicated independently. No-
tably, the CLIP score validation in our patient population 
is consistent with prior studies of Western HCC patient 
populations. Notably, a substantial number of our pa-
tients had advanced BCLC stages B–D (239 patients, 
82.9%). Therefore, the superiority of CLIP over BCLC in 
our advanced (or unresectable) HCC patient population, 
the standard clinical trials population, is also consistent 
with prior studies of patients with advanced HCC, since 
BCLC staging of this patient population is challenged. 
However, evaluating the incorporation of IGF-1 and oth-
er biologically pertinent biomarkers into BCLC staging
of more diverse patient populations, in addition to eval-
uating other commonly used HCC staging systems, may 
prove useful in the assessment of HCC prognosis and 
hence in guiding the treatment decisions and patients’ 
stratification in clinical trials. While none of these stag-
ing systems is yet approaching routine clinical use, rapid 
growth in plasma biomarkers assay technology may pro-
vide new avenues for non-invasive ways of assessing the 
severity of CLD and the biology of HCC tumors, and may 
prove beneficial after incorporation into the HCC staging 
systems to refine patients’ stratification.
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 Fig. 2. Kaplan-Meier plots for CLIP groups. OS = Overall survival.  Fig. 3. Kaplan-Meier plots for I-CLIP groups. OS = Overall sur-
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 Our study has some limitations. First, our study cutoff 
point was based on the recursive portioning method that 
identified the best cutoff point which correlated with the 
survival of our patient population; therefore, the IGF-1 
cutoff point may differ in other patient populations. 
However, choosing an optimal cutoff point for plasma 
biomarkers in cancer research remains challenging in 
general, given the possible daily variations in the circulat-
ing levels and the potential effects of patients’ genetics, 
nutritional status, gender, and age. Nevertheless, our re-
sults clearly indicate that the IGF-1 cutoff point we iden-
tified was independent of and complementary to our pa-
tients’ clinicopathologic prognostic factors. Moreover, 
additional independent studies in other patient popula-
tions are warranted, not only to confirm our concept, but 
also to possibly help to identify an optimal range to be 
used in this setting. Additionally, we utilized the com-
mercially available ELISA kits to measure plasma IGF-1 
and VEGF. Although the methodology is reproducible in 
expert research facilities, the measurement should be 
done in a Clinical Laboratory Improvement Amend-
ments (CLIA)-certified laboratory before using it in clin-
ic to guide therapy decisions. Furthermore, while 394 
HCC patients signed consent forms to participate in the 
study, baseline plasma samples were available for 288 pa-
tients only. The main reason for missing blood samples 
collection was mainly related to insufficient time to ob-
tain blood samples during the initial assessment in clinic. 
However, our analysis indicated that there were no major 
differences between both groups as aforementioned. Fi-
nally, our findings are based on a single institution expe-
rience and will need to be validated prospectively in oth-
er centers and patient populations. Furthermore, mea-
suring IGF-1 carrier binding protein, IGFBP-3 and serum 
protease activity, the main determinants of the circulat-
ing level of IGF-1, may shed more light on the IGF-1 path-
way in CLD and HCC, and will also confirm the utility 
of plasma IGF-1 in assessing the severity of the liver con-
dition in CLD and HCC. Interestingly, recent studies of 
circulating IGF-1 in cancer patients  [28–31] found that 
high IGF-1 level was associated with a higher risk of can-
cer. However, the goal of our current study was to evalu-
ate the level of IGF-1, as a marker of the underlying syn-
thetic function of the liver. Finally, the majority of our 
patient population had advanced unresectable disease. 
However, this population represents the classic patient 
population of the HCC clinical trials, who critically need 
new approaches to improve their prognostic stratifica-
tion, which is crucial in comparing and interpreting trial 
results and also in decision making in clinical practice.
 In conclusion, searching for new tools of assessment of 
the hepatic reserve in patients with HCC is essential to 
improving their prognostic stratification. This approach 
will directly affect therapy decisions, treatment outcome, 
and refine advanced HCC patients’ stratification in clin-
ical trials. Our study results indicate that lower baseline 
plasma level of IGF-1 correlated with advanced clinico-
pathologic parameters of patients with HCC. The inte-
gration of IGF-1 into the CLIP score (I-CLIP) significant-
ly improved prognostic stratification of patients with
advanced HCC. However, independent validation of our 
study is warranted.
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